Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

NCT ID: NCT01047358

Last Updated: 2015-10-08

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

206 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-06-30

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This non-interventional study is to monitor use in real practice in Korea including adverse events on Aromasin (Exemestane).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All cases at the participating institutions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ajuvant group

adjuvant setting after two to three years of tamoxifen

Aromasin

Intervention Type DRUG

25 mg table QD

palliative group

palliative setting after progression of disease with anti-estrogen therapy

Aromasin

Intervention Type DRUG

25 mg table QD

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aromasin

25 mg table QD

Intervention Type DRUG

Aromasin

25 mg table QD

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

exemestane exemestane

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \- Postmenopausal women with breast cancer eligible for hormonal therapy.

Exclusion Criteria

* Pregnant breast-feeding premenopausal.
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Soon Chun Hyang University Hospital Cheonan

Cheonan, Chungcheongnam-do, South Korea

Site Status

Hallym University Sacred Heart Hospital

Anyang-si, Gyeonggi-do, South Korea

Site Status

Soon Chun Hyang University Bucheon Hospital

Bucheon-si, Gyeonggi-do, South Korea

Site Status

Myongji Hospital, Kwangdong Unversity College of Medicine

Goyang-si, Gyeonggi-do, South Korea

Site Status

Wonkwang University School of Medicine and Hospital (WUH)

Iksan -si, Jeollabuk-do, South Korea

Site Status

Asan Medical Center

Seoul, Korea, South Korea

Site Status

Seoul National University Hospital (SNUH)

Seoul, Seoul, South Korea

Site Status

Hwasun Hospital, Chonnam National University

Cheonnam, South Jeolla Province, South Korea

Site Status

Inje University Busan Paik Hospital

Busan, , South Korea

Site Status

Yeung Nam University Hospital

Daegu, , South Korea

Site Status

Seoul National University Bundang Hospital

Gyeonggi-do, , South Korea

Site Status

Inha University Hospital

Incheon, , South Korea

Site Status

Cheil General Hospital & Women's Healthcare Center

Seoul, , South Korea

Site Status

Seoul National University Hospital

Seoul, , South Korea

Site Status

Severance Hospital, Yonsei University Health System, Yonsei Cancer Center

Seoul, , South Korea

Site Status

Samsung Medical Center

Seoul, , South Korea

Site Status

Korea University Anam Hospital

Seoul, , South Korea

Site Status

Asan Medical Center, University of Ulsan

Seoul, , South Korea

Site Status

Korea University Medical Center (KUMC) - Korea University Guro Hospital

Seoul, , South Korea

Site Status

SMG-SNU Boramae Medical Center

Seoul, , South Korea

Site Status

Ewha Womans University Mokdong Hospital

Seoul, , South Korea

Site Status

Ajou University Hospital

Suwon, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Related Links

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A5991089

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.